Wu Ruicheng, Li Dengxiong, Zhang Facai, Bai Yunjin, Wang Xiaoming, Han Ping
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Front Surg. 2022 May 23;9:907485. doi: 10.3389/fsurg.2022.907485. eCollection 2022.
The objective of this study was to investigate the platelet-to-lymphocyte ratio (PLR) in patients who underwent intravesical treatment for non-muscle invasive bladder cancer (NMIBC). A total of 197 patients who underwent intravesical Bacillus Calmette-Guerin treatment after transurethral resection of bladder (TURB) were included. We divided the patients into different groups according to the treatment stage before and during induction treatment as Group 1 and Group 2, and set the change value of PLR as the Group 3. The cutoff values of PLR were determined through receiver operation characteristics curves analysis. we found a significant difference in recurrence-free survival (RFS) and progression-free survival (PFS) between patients with high serum PLR and those with low serum PLR in Group 1, as well as Group 2. Cox multivariate analysis revealed that tumor number ≥3, high grade, and history of carcinoma in situ (CIS) were significant factors predicting RFS and PFS. The PLR values before and during induction therapy could be used as predictors for the progression and recurrence of NMIBC patients receiving BCG immunotherapy. the PLR values after induction therapy have a stronger predictive power.
本研究的目的是调查接受非肌层浸润性膀胱癌（NMIBC）膀胱内治疗的患者的血小板与淋巴细胞比值（PLR）。总共纳入了197例经尿道膀胱肿瘤电切术（TURB）后接受膀胱内卡介苗治疗的患者。我们根据诱导治疗前和诱导治疗期间的治疗阶段将患者分为不同组，即第1组和第2组，并将PLR的变化值设为第3组。通过受试者工作特征曲线分析确定PLR的临界值。我们发现第1组以及第2组中，血清PLR高的患者与血清PLR低的患者在无复发生存期（RFS）和无进展生存期（PFS）方面存在显著差异。Cox多因素分析显示，肿瘤数量≥3、高级别以及原位癌（CIS）病史是预测RFS和PFS的重要因素。诱导治疗前和诱导治疗期间的PLR值可作为接受卡介苗免疫治疗的NMIBC患者进展和复发的预测指标。诱导治疗后的PLR值具有更强的预测能力。
